XTL Biopharmaceuticals Licenses Biossil's hCDR1 for Lupus Treatment

XTL Biopharmaceuticals has entered into a sublicensing agreement with Biossil for the treatment of autoimmune diseases. The agreement involves the use of XTL's hCDR1 peptide for systemic lupus erythematosus and Sjogren's syndrome, and recombinant human erythropoietin (rHuEPO) for multiple myeloma. hCDR1 acts as a disease-specific treatment that modifies the autoimmune process, while rHuEPO stimulates erythropoiesis to promote red blood cell production.

XTL Biopharmaceuticals (XTL), an Israeli-based biopharmaceutical company, has recently entered into a sublicensing agreement with Biossil, a leading biotechnology company [1]. This strategic move grants Biossil the rights to use XTL's hCDR1 peptide and recombinant human erythropoietin (rHuEPO) for the treatment of various autoimmune diseases.

The hCDR1 peptide, a disease-specific treatment developed by XTL, acts as a modifier of the autoimmune process [2]. By targeting specific diseases, hCDR1 has the potential to revolutionize the way autoimmune diseases are treated. In this agreement, Biossil will use hCDR1 to treat systemic lupus erythematosus (SLE) and Sjogren's syndrome, two debilitating autoimmune diseases.

In addition to hCDR1, Biossil will also utilize XTL's rHuEPO for the treatment of multiple myeloma [2]. rHuEPO, a stimulant for erythropoiesis, promotes the production of red blood cells. This therapy is crucial for patients with multiple myeloma, a cancer that affects the production of healthy blood cells.

XTL's recent acquisition of THE SOCIAL PROXY Ltd., an AI web data company, is expected to bolster the company's financial position and enable it to further invest in research and development [1]. The closing of this transaction is subject to customary closing conditions and the receipt of necessary approvals.

This strategic partnership between XTL and Biossil demonstrates XTL's commitment to leveraging its innovative technologies to develop novel treatments for autoimmune diseases. With the potential to revolutionize the treatment landscape for these debilitating conditions, XTL is poised for significant growth and success in the biopharmaceutical industry.

References:
[1] GlobeNewswire. XTL Biopharmaceuticals Announces Definitive Agreement to Acquire THE SOCIAL PROXY Ltd. https://www.globenewswire.com/news-release/2024/06/05/2893929/0/en/XTL-Entered-Definitive-Agreement-to-Acquire-The-Social-Proxy.html
[2] XTL Biopharmaceuticals. XTL Biopharmaceuticals Enters into Sublicensing Agreement with Biossil for the Treatment of Autoimmune Diseases. https://www.xtlbiopharma.com/news-and-events/press-releases/detail/2024/xtl-biopharmaceuticals-enters-into-sublicensing-agreement-with-biossil-for-the-treatment-of-autoimmune-diseases